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OBJECTIVES We sought to study the prognostic value of dobutamine echocardiography in patients with
nonischemic dilated cardiomyopathy (DCM) and prognostically borderline values of peak
oxygen consumption (VO2max) during exercise.
BACKGROUND Changes in echocardiographic variables assessed by dobutamine echocardiography can be
used to evaluate the functional status of patients with chronic heart failure (CHF) and DCM.
METHODS In 27 consecutive patients (mean age 55 6 15 years) with VO2max values between 10 and
14 ml/kg body weight per min, a low infusion rate (10 mg/kg per min) dobutamine
echocardiographic test was performed. The induced changes in echocardiographic variables
were measured, and an 18-month follow-up study was done.
RESULTS At the end of the protocol, 9 patients (group I) had died from cardiac reasons, whereas the
remaining 18 patients (group II) survived. After dobutamine infusion, the left ventricular
end-systolic diameter (LVESD) was smaller in group II (6.22 6 0.94 cm) than in group I
(6.99 6 0.76 cm; p , 0.05), whereas end-systolic wall stress (ESWS) was higher in group I
(1030.66 6 193.98 g/cm2) than in group II (691.57 6 297.06 g/cm2; p , 0.05). The changes
in LVESD and ESWS were greater in group I (0.75 6 0.36 cm and 463.11 6 159.87 g/cm2,
respectively) than in group II (20.04 6 0.36 cm and 83.16 6 291.74 g/cm2, respectively; p ,
0.01 for both).
CONCLUSIONS In the “gray” zone of VO2max, dobutamine echocardiography seems to be a valuable prog-
nostic indicator in patients with CHF and DCM. (J Am Coll Cardiol 2001;37:1685–91)
© 2001 by the American College of Cardiology
Recent American Heart Association consensus statements
have recommended that peak oxygen consumption
(VO2max) during exercise can be used to objectively evalu-
ate the functional status of patients with heart failure (1).
However, several groups have found no statistical difference
in survival between patients with VO2max levels in the
range of 10 to 14 ml/kg body weight per min and those with
levels in the range of 14 to 18 ml/kg per min (2). Although
the decision for heart transplantation in patients with
chronic heart failure (CHF) is mainly based on VO2max
values, it has been suggested that patients who present with
an increase in VO2max of at least 2 ml/kg per min at
follow-up have a short-term survival, similar to those who
had received a heart transplant (3), suggesting that this
variable may vary throughout the course of the disease.
Recently, we have found that the changes in echocardio-
graphic variables assessed by dobutamine echocardiography
are well correlated with VO2max and seem to be accurate
for evaluating the functional status of patients with CHF
and nonischemic dilated cardiomyopathy (DCM) (4).
The aim of this study was to investigate the prognostic
value of dobutamine echocardiography in patients with
nonischemic DCM and prognostically borderline values of
VO2max (10 to 14 ml/kg per min).
METHODS
Patients. Twenty-nine consecutive patients with docu-
mented DCM were studied. Included were patients with
VO2max values between 10 and 14 ml/kg per min, mea-
sured on the day before the dobutamine echocardiographic
study. Twenty-seven patients (98%; 20 men and 7 women,
mean age 57 6 8 years) with good-quality M-mode and
two-dimensional echocardiograms were recruited for anal-
ysis. The diagnosis of DCM was based on the echocardio-
graphic findings of 1) a dilated left ventricle (left ventricular
end-diastolic diameter [LVEDD] .60 mm), with severely
affected systolic function; 2) fractional shortening [FS]
,20%; and 3) ejection fraction ,35%. Dilated cardiomy-
opathy was classified as idiopathic in all patients on the basis
of their clinical history (no history of alcohol consumption,
myocardial infarction, hypertension, valvular heart disease
or familial hypertrophic cardiomyopathy and no evidence of
restrictive cardiomyopathy), echocardiogram, coronary an-
giogram (angiographic lesions ,30% lumen diameter ste-
nosis) and biopsy. All patients were in New York Heart
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Association functional class III. All patients were in sinus
rhythm and were taking digoxin, angiotensin-converting
enzyme inhibitors and diuretic drugs in adequate doses. All
of them received the same level of care and equal access to
heart transplantation. None of them had placement of a left
ventricular assist device, and the dobutamine echocardio-
graphic results were not used to determine the type of care
these patients received. Patients with rhythm disturbances,
ischemic cardiomyopathy, more than mild valvular heart
disease or regional wall motion abnormalities were excluded.
Transthoracic echocardiography was performed, and the
echocardiographic variables were measured at baseline and
after dobutamine infusion. Each patient was followed for 18
months by monthly clinical visits, and in case of a terminal
event, information was acquired from either the physician or
the hospital archives. All patients were prospectively iden-
tified into two groups: those who died (group I) or survived
(group II) after the 18-month follow-up period. The groups
were analyzed after completion of the study to evaluate the
prognostic importance of dobutamine echocardiographic
variables. All patients gave written, informed consent.
Echocardiography. Measurements and tracings were car-
ried out according to the principle of the leading edge, in
accordance with the recommendations of the American
Society of Echocardiography (5). Left ventricular dimen-
sions and wall thickness were measured from parasternal
targeted M-mode echocardiographic recordings. Care was
taken to record the largest and smallest left ventricular
dimensions present between the tips of the mitral valve
leaflets and the superior aspect of the papillary muscles. The
LVEDD was taken at the Q-wave of the electrocardiogram
(ECG). The left ventricular end-systolic diameter
(LVESD) was determined to be the shortest distance
between the walls (6). Using a Hewlett-Packard (Sonos
1000 or 2500; Palo Alto, California) ultrasound device, the
following echocardiographic variables were measured at
baseline and at the end of 10 mg/kg per min of dobutamine
infusion: 1) FS 5 ([LVEDD 2 LVESD]/LVEDD) 3
100; 2) ventricular septal and posterior wall thickness in
systole (PWTs); 3) end-systolic (meridional) wall stress
(ESWS), calculated using the formula: systolic blood pres-
sure (SBP) 3 LVESD 3 1.35/4 3 PWTs 3 (1 1
PWTs)/LVESD (7) (SBP was represented by brachial
artery systolic pressure and was measured every minute with
a cuff sphygmomanometer); 4) left ventricular heart rate–
corrected mean velocity of circumferential fiber shortening
(Vcfc), calculated as follows: Vcfc 5 (%FS/LVET) 3 RR
(LVET represents left ventricular ejection time in millisec-
onds from the opening to the closing clicks of the aortic
valve flow velocity envelope, as measured by continuous
wave Doppler imaging); 5) Vcfc/ESWS ratio; 6) cardiac
output, calculated as the product of stroke volume 3 heart
rate (stroke volume was calculated according to the formula:
p/4 3 [aortic diameter]2 3 aortic velocity-time integral)
(aortic diameter was measured in a two-dimensional
parasternal long-axis view, just below the aortic orifice [8];
aortic velocities were measured by continuous wave Doppler
imaging in an apical five-chamber view); and 7) left ven-
tricular ejection fraction, calculated using the modified
Simpson’s rule.
Left ventricular myocardial reserve was defined as the
changes in the aforementioned echocardiographic variables
after dobutamine infusion. The Vcfc/ESWS ratio was also
measured as an index of myocardial contractile reserve.
Changes represent the values obtained after inotropic stim-
ulation, minus those obtained at baseline. All measurements
were made at a paper speed of 100 mm/s and represent the
average of the measurements of five consecutive beats. All of
the patients’ echocardiograms were analyzed by two inde-
pendent, expert observers. In cases of discrepancy, the
average was calculated, and the mean value was reported.
Dobutamine infusion. Dobutamine was infused intrave-
nously in two steps after establishment of a stable hemody-
namic state for each step (heart rate and blood pressure had
achieved a plateau for the last 2 to 3 min). The duration of
each step was 5 min, and the maximal end dose of infused
dobutamine was 10 mg/kg per min (9). At each step,
dobutamine infusion was increased by 5 mg/kg per min,
reaching 10 mg/kg per min at the second step. Every minute
during the protocol, systolic, diastolic and hence mean
arterial blood pressures (Sirecust 888 device, Siemens), heart
rate and a 12-lead ECG were recorded.
Cardiopulmonary exercise testing. Exercise testing with
respiratory gas exchange measurements was performed by
using the Medgraphics CPX/MAX measuring system,
while patients exercised on a treadmill according to the
Dargie protocol (10). Blood pressure was measured with a
mercury sphygmomanometer, and the ECG was continu-
ously monitored with a computer-assisted system (Mar-
quette Electronics Inc., Milwaukee, Wisconsin). All pa-
tients quit the test because of dyspnea or fatigue, and in all
patients, the gas exchange anaerobic threshold and a respi-
ratory exchange ratio .1.0 were reached. Peak oxygen
consumption (VO2max, ml/kg per min) during exercise was
reported as the mean value during the last minute of
exercise.
Statistical analysis. All data are expressed as the mean
value 6 SD. The data were processed and analyzed using
the programs Statistica and SPSS for Windows 98. At this
Abbreviations and Acronyms
CHF 5 chronic heart failure
DCM 5 dilated cardiomyopathy
ESWS 5 end-systolic (meridional) wall stress
FS 5 fractional shortening
LVEDD 5 left ventricular end-diastolic diameter
LVESD 5 left ventricular end-systolic diameter
PWTs 5 posterior wall thickness in systole
SBP 5 systolic blood pressure
Vcfc 5 left ventricular heart rate-corrected mean
velocity of circumferential fiber shortening
VO2max 5 peak exercise oxygen consumption
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stage, we added categorical and grouping variables. Every
variable was analyzed with regard to its statistical power,
producing tables of descriptive statistics according to the
group (I 5 terminal; II 5 survival). The Kolmogorov-
Smirnov procedure was applied to determine normality.
Because a number of variables did not follow the normal
distribution, we opted for use of nonparametric tests in
paired and independent sample comparisons. The Wilcoxon
test was used for paired comparisons, such as comparisons of
echocardiographic variables before and after dobutamine
infusion. The Kolmogorov-Smirnov test was used for inde-
pendent sample comparisons, such as comparisons of echo-
cardiographic variables between the two groups. Pairwise
comparisons were used to assess: 1) the effect of dobutamine
infusion (before and after the end of 10 mg/kg per min of
dobutamine infusion); and 2) the potential of any given
echocardiographic variable to serve as a prognostic factor.
Variables that exhibited statistically significant differences
between the terminal and survival groups were considered
for inclusion in a prediction model constructed according to
the logistic regression estimation method. Interobserver and
intraobserver variabilities of our laboratory have been re-
ported recently (4). A p value ,0.05 was considered
statistically significant.
RESULTS
No major side effects were reported during dobutamine
infusion. The VO2max measured in all patients ranged from
10.2 to 13.9 ml/kg per min (mean 12.4 6 1, median 12.2).
The VO2max and anaerobic threshold were similar between
groups (12.1 6 1.3 and 7.35 6 1.1 ml/kg per min for group
I and 12.53 6 0.8 and 7.35 6 0.89 ml/kg per min for group
II, respectively).
Echocardiographic measurements. The echocardiographic
measurements of the entire study group, before and after
dobutamine infusion, are shown in Table 1. After dobut-
amine infusion, an increase in LVEDD was observed in the
entire study group (p , 0.05), as well as in both subgroups.
However, only in group I was this significantly increased
(p , 0.05). This might be due to the selection of a particular
group of patients in whom the effect of dobutamine infusion
on ESWS exceeded its effect on contractility. Therefore, left
ventricular stroke volume seems to be maintained, probably
by enhancement of LVEDD.
18-month follow-up. All patients were prospectively iden-
tified into two groups according to whether they died (group
I, n 5 9) or survived (group II, n 5 18) after 18 months of
follow-up.
The values of the echocardiographic variables for groups
I and II, before and after dobutamine infusion, are shown in
Table 2 and Figures 1 and 2. Although, at baseline, all
echocardiographic variables were similar between groups
after inotropic stimulation, LVESD and ESWS were
higher in group I than in group II (p , 0.05 for both).
Systolic and mean blood pressures, as well as heart rate, were
similar between groups, both before and after dobutamine
infusion. Interestingly, the changes in left ventricular pos-
terior wall thickness (p , 0.05), LVESD (p , 0.01), ESWS
(p , 0.01) and Vcfc/ESWS ratio (p , 0.05) were statisti-
cally different between the groups (Table 3, Fig. 3, 4).
Prediction model. In constructing a prediction model for a
dependent dichotomous variable such as survival (only two
possible outcomes), without affecting the continuity of the
independent variables, one must use a special regression
model. The logistic regression model describes the relation-
ship between a group of independent variables that may be
continuous or categorical and one binary (dichotomous)
dependent variable. In our case, the dependent binary
variable is the possible outcome (death or survival), and the
candidate independent variables for inclusion in the model
Table 1. Echocardiographic and Other Measurements Before and After Dobutamine Infusion in
the Entire Study Group (n 5 27)
Variable Before After Change p Value
IVSs (cm) 0.95 6 0.15 0.97 6 0.16 0.16 6 0.14 NS
PWTs (cm) 1.19 6 0.22 1.06 6 0.26 20.13 6 0.18 ,0.01
LVEDD (cm) 7.23 6 0.87 7.49 6 0.98 0.25 6 0.48 ,0.05
LVESD (cm) 6.26 6 0.81 6.4 6 0.94 0.28 6 0.49 NS (0.06)
FS (%) 13.5 6 2.87 13.89 6 2.92 0.39 6 3.92 ,0.01
2-D LVEF (%) 23.43 6 4.33 24.13 6 3.42 0.70 6 2.85 ,0.05
SV (ml) 41.04 6 6.83 49.95 6 9.3 8.9 6 6.13 ,0.001
CO (liters/min) 3.41 6 0.29 3.94 6 0.33 0.64 6 0.44 ,0.001
ESWS (g/cm2) 594.79 6 277.71 804.60 6 309.53 209.81 6 311.18 ,0.01
Vcfc (circ/s) 0.38 6 0.09 0.36 6 0.07 20.02 6 0.11 NS
Vcfc/ESWS (circzcm2/gzs) 0.0008 6 0.0004 0.0006 6 0.0004 20.0002 6 0.0004 ,0.05
SBP (mm Hg) 109.0 6 8.94 110.85 6 7.08 1.85 6 8.19 NS
MBP (mm Hg) 76.37 6 5.73 67.11 6 4.8 29.2 6 3.94 ,0.001
RR interval (ms) 754.04 6 45.54 688.58 6 41.68 265.46 6 52.06 ,0.001
Data are presented as mean values 6 SD.
CO 5 cardiac output; 2-D 5 two-dimensional; ESWS 5 end-systolic wall stress; FS 5 fractional shortening; IVSs 5
intraventricular septum at systole; LVEF 5 left ventricular ejection fraction; LVEDD and LVESD 5 left ventricular
end-diastolic and end-systolic dimension, respectively; MBP 5 mean blood pressure; PWTs 5 posterior wall thickness in
systole; SBP 5 systolic blood pressure; SV 5 stroke volume; Vcfc 5 left ventricular heart rate-corrected mean velocity of
circumferential fiber shortening.
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are the changes in LVESD, ESWS, Vcfc/ESWS ratio and
PWTs. The single independent variable that explained most
of the dependent variable’s variability is the change in
LVESD, with the change in ESWS a close second (66.6%
for positive and 94.4% for negative predictive accuracy for
both). The model we derived, using the Hooke-Jeeves
pattern moves and quasi Newton approach, involves three
variables—changes in PWTs, LVESD and ESWS—and
explains most of the dependent variable’s variability. Ac-
cording to this model, the dependent variable is predicted by
the function: Outcome 5 exp (b0 1 b1 3 change in PWTs
1 b2 3 change in LVESD 1 b3 3 change in ESWS)/ {1
exp (b0 1 b1 3 change in PWTs 1 b2 3 change in LVESD
1 b3 3 change in SWS)} where b0 5 5.75; b1 5 219.72;
b2 5 23.17; and b3 5 20.02. This model delivers 88.9%
predictive accuracy, both positively and negatively.
DISCUSSION
The results of this study showed that inotropic stimulation
with dobutamine, in patients with nonischemic DCM and
borderline values of VO2max during exercise, leads to an
Figure 1. The left ventricular end-systolic diameter (LVESD) response to dobutamine in the terminal (group I, n 5 9) and survival (group II, n 5 18)
groups.
Table 2. Echocardiographic Variables Before and After Dobutamine Infusion in the Terminal (Group I, n 5 9) and Survival (Group
II, n 5 18) Groups
Variable
Group I Group II
Before After
p
Value Before After
p
Value
IVSs (cm) 0.98 6 0.16 1.02 6 0.17 NS 0.93 6 0.15 0.94 6 0.15 NS
PWTs (cm) 1.16 6 0.09 0.93 6 0.09 ,0.0 1.20 6 0.27 1.13 6 0.29 NS
LVEDD (cm) 7.23 6 0.65 7.76 6 0.78 ,0.05 7.23 6 0.98 7.35 6 1.05 NS
LVESD (cm) 6.24 6 0.66 6.99 6 0.76 ,0.01 6.27 6 0.9 6.22 6 0.94 NS
FS (%) 13.87 6 3.24 13.26 6 3.01 NS 13.31 6 2.75 14.2 6 2.91 NS
2-D LVEF (%) 24.05 6 5.03 24.29 6 4.36 NS 23.12 6 4.06 24.06 6 3 NS
SV (ml) 43.78 6 3.53 53.84 6 5.78 ,0.01 39.67 6 7.71 48 6 10.22 ,0.01
CO (liters/min) 3.3 6 0.18 3.79 6 0.33 ,0.01 3.47 6 0.32 4.02 6 0.31 ,0.01
ESWS (g/cm2) 567.55 6 114.44 1030.66 6 193.98 ,0.01 608.42 6 333.48 691.57 6 297.06 NS
Vcfc (circ/s) 0.39 6 0.09 0.35 6 0.09 NS 0.38 6 0.08 0.37 6 0.07 NS
Vcfc/ESWS (circzcm2/gzs) 0.0007 6 0.0003 0.0003 6 0.0009 NS 0.0008 6 0.0004 0.0007 6 0.0005 NS
SBP (mm Hg) 107.78 6 9.74 111.67 6 7.07 NS 109.61 6 8.74 110.44 6 7.26 NS
MBP (mm Hg) 77.89 6 5.53 68.11 6 5.01 ,0.01 75.61 6 5.83 66.61 6 4.75 ,0.01
RR interval (ms) 755.83 6 37.37 705.64 6 36.81 ,0.01 753.15 6 50.12 680.05 6 42.28 ,0.01
Data are presented as mean values 6 SD.
Abbreviations as in Table 1.
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improvement in indexes of left ventricular performance. In
addition, this study shows that the changes in ESWS and
the Vcfc/ESWS ratio observed after inotropic stimulation
may represent an alternative way of assessing the functional
status of the heart. Importantly, it seems that the changes in
these echocardiographic variables can identify high risk
patients.
Echocardiographic changes after inotropic stimulation.
In keeping with previous reports (11), we observed that after
low-dose dobutamine infusion, left ventricular performance
indexes were increased. Numerous attempts have been made
to assess ventricular performance noninvasively. However,
left ventricular ejection fraction, though a good index of left
ventricular performance, is affected mainly by afterload and
does not adequately reflect exercise capacity or severity of
functional class (12).
In this study, dobutamine infusion did not affect Vcfc,
whereas the Vcfc/ESWS ratio, an index that incorporates
afterload, was significantly decreased, suggesting that the
contractility indexes are mainly affected by afterload (13).
Because left ventricular afterload increased after dobutamine
infusion, it seems likely that myocardial contractility in
these patients did not result in a decrease in left ventricular
internal load (14). In this respect, concerning this group of
patients, the observed rise in ESWS implies that the effect
of dobutamine infusion on ESWS exceeded its effect on
contractility. Accordingly, the results of this study indicate
that the changes in ESWS induced by dobutamine infusion
were greater in the patients who died during the 18-month
follow-up period than in those who survived, suggesting a
different unloading response to dobutamine. The ability of
the ventricle to unload itself is crucial to the maintenance of
Figure 2. The end-systolic (meridional) wall stress (SWS) response to dobutamine in the terminal (group I, n 5 9) and survival (group II, n 5 18) groups.
Table 3. Changes and Percent Changes in Echocardiographic Variables in the Terminal
(Group I, n 5 9) and Survival (Group II, n 5 18) Groups
Variable Group I (% change) Group II (% change)
p
Value
IVSs (cm) 0.03 6 0.16 (3.06) 0.009 6 0.14 (0.97) NS
PWTs (cm) 20.23 6 0.09 (219.83) 20.08 6 0.2 (26.67) ,0.05
LVEDD (cm) 0.53 6 0.51 (7.33) 0.12 6 0.41 (1.66) NS
LVESD (cm) 0.75 6 0.36 (12.02) 20.04 6 0.36 (20.64) ,0.01
FS (%) 20.61 6 4.55 (24.40) 0.89 6 3.6 (6.69) NS
2-D LVEF (%) 0.23 6 3.46 (0.96) 0.93 6 2.57 (4.02) NS
SV (ml) 10.06 6 3.88 (22.98) 8.32 6 7.02 (20.97) NS
CO (liters/min) 0.49 6 0.32 (14.85) 0.71 6 0.48 (20.46) NS
ESWS (g/cm2) 463.11 6 159.87 (81.60) 83.16 6 291.74 (13.67) ,0.01
Vcfc (circ/s) 20.04 6 0.14 (210.26) 20.01 6 0.1 (22.63) NS
Vcfc/ESWS (circzcm2/gzs) 20.0004 6 0.0003 (257.14) 20.0001 6 0.0004 (212.50) ,0.05
Data are presented as mean values 6 SD.
Abbreviations as in Table 1.
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normal myocardial mechanics, because it is the wall stress
that determines the overall extent and mean velocity of fiber
shortening (15). Because wall stress incorporates LVESD
and end-systolic PWT, is not surprising that the changes in
these variables can also determine patients who will be alive
after 18 months. The importance of LVESD and PWT
have been well documented by other investigators (16,17).
However, it should be pointed out that the specific dobut-
amine echocardiographic variables investigated in this study
might provide valuable prognostic information for the group
of patients with VO2max values of borderline significance,
rather than for any individual patient.
Figure 3. Dobutamine-induced changes in left ventricular end-systolic diameter (ESD).
Figure 4. Dobutamine-induced changes in end-systolic (meridional) wall stress (SWS).
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Study limitations. 1) The heterogeneous contractile re-
sponses to dobutamine observed in this study, among
patients with CHF, have been reported previously and may
reflect differences in beta-1-adrenoreceptor density, which
was not investigated in this study. Although the response to
dobutamine may underestimate the contractile reserve of
the failing myocardium, the magnitude of the drug’s
effect appears to decline as left ventricular function
deteriorates, and this is accompanied by a reduction in
beta-1-adrenoreceptor density (18). 2) Brachial artery pres-
sure was used to calculate peak SBP. Although numerous
validation studies have been performed (19), we recognize
that brachial artery pressure is only an estimate of left
ventricular ejection pressure, and not a direct measurement.
In addition, there is a lack of synchrony because of estimates
of ventricular pressure (which occurred at early or mid
ejection) and those of cavity dimensions and wall thickness
(which occurred at the end of ejection). However, because
the main purpose of this study was to estimate wall stress
before and after inotropic stimulation, we assumed that the
method used in this study for the measurement of peak SBP
had little influence on the final results. Although the peak
(as opposed to end-systolic) pressure was used in this study,
previous reports have shown that this substitution is reason-
able (20). However, measurements of peak SBP are less
accurate than those of end-systolic pressure, most likely
because there is a variable degree of neurohumoral activation
and responsiveness in this selected group of patients.
Clinical implications. The induced changes in LVESD,
ESWS and the more sophisticated Vcfc/ESWS ratio seem
to represent the simplest, easiest way to detect the func-
tional status of patients with CHF, and, more importantly,
these changes represent indexes of survival. This might be of
great importance, because in this category of patients,
VO2max might be influenced by noncardiac factors, and
VO2max, per se, cannot provide significant information.
Conclusions. In the “gray” zone of VO2max, dobutamine
echocardiographic variables seem to be valuable prognostic
indicators in patients with CHF and nonischemic DCM.
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